Efficacy of different doses of atorvastatin treatment on serum levels of 8-hydroxy-guanin (8-OHdG) and cardiac function in patients with ischemic cardiomyopathy.

Objective:��Tocomparetheefficacyof�40�mgandl0�mgatorvastatinonserumlevelsof�8-Hydroxy-Guanin� (8-OHdG)�andthecardiacfunctioninpatientswithischemiccardiomyopathy�(ICM). Methods: OnehundredtwentythreehospitalizedICMpatientsand�120�healthycontrolswereincluded� inthisstudy.�Allsubjectswererandomlydividedintotwogroups:�10�mg/datorvastatingroup�(n=62)�and� 40�mg/datorvastatingroup�(n=61).�SerumlevelsofC-reactiveprotein�(CRP),�creatinekinase,�glutamic- pyruvictransaminase,�lipidsandB-typenatriureticpeptide�(BNP)�weretestedinallsubjectsbothatthe� initialphaseandtheterminalphaseofthisstudy.�Adversedrugreactioneventswererecordedinthisstudy.� Echocardiographicmethodwasappliedtocomparethecardiacfunctionbeforeandaftertreatmentin� thedoubleblindstudy.�Serum�8-OHdGlevelsweretestedbyenzyme-linkedimmunosorbentassay�(ELISA)� beforeandaftertreatment,�andtheresultsinatorvastatintreatmentgroupswerecomparedwiththe� healthycontrols. Results:�Serum�8-OHdGlevelsinICMpatientsweresignificantlyhigherthanthatinnormalcontrolgroups� (p<0.05).�TherewassignificantdifferenceofSerum�8-OHdGlevelsin�40�mg/datorvastatingroup�(p<0.05),� butwasnosignificantdifferencein�10�mg/datorvastatingroupbeforeandafterthetreatment.�The� 8-OHdGlevelin�40�mg/datorvastatingroupwassignificantlylowerthanthatin�10�mg/datorvastatingroup� beforethetreatmentaswellasafterthetreatment�(p<0.05).�Thesystolicanddiastolicfunctionimproved� significantlyin�40�mg/datorvastatingroupbeforeandaftertreatment,�aswellasincomparisonwith�10� mg/datorvastatingroup�(p<0.05). Conclusion: Serum�8-OHdGpossiblyplaysanimportantroleinthepathogenesisofICM.�Atorvastatinissafe� andeffectiveinICMtreatment;�furthermoreatorvastatinwhichalsohasindependentlipidloweringeffect,� issignificantlybetterinthedoseof�40�mg/day.